KRAS and acute lymphoblastic leukemia: We also observed that the AMD1 protein level was increased in RASmt cells compared to controls and were downregulated by inhibiting mTOR signaling pathway with mTOR kinase inhibitor AZD-8055 in RASmt cells (Figures 6B and S4), a finding consistent with our previous conclusion that the KRAS-G12D mutation somehow promotes the catabolism of Met in support of polyamine biosynthesis in B-ALL cells.